Ensysce Biosciences Inc (ENSC)

Form EFFECT - Notice of Effectiveness

Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study

~ ~ Advances First-in-Class, Breakthrough Therapy-Designated Opioid Engineered to Protect Against Oral Overdose ~ ~ SAN DIEGO, CA / ACCESS...

Ensysce Biosciences Reports First Quarter 2026 Financial Results

~ IRB Approval Secured for PF614-MPAR-102 Part 3 ~~ Clinical Peer-Reviewed Data Published for First Overdose Protected Opioid PF614-MPAR®;...

Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology

~ Patent Extends Jurisdiction and Protection Through 2042 ~ SAN DIEGO, CA / ACCESS Newswire / May 12, 2026 / Ensysce Biosciences, Inc...

Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam

~ Chemical Control, Clinical Confidence: Rethinking Opioids ~ SAN DIEGO, CA / ACCESS Newswire / May 8, 2026 / Ensysce Biosciences, Inc...

Form S-8 - Securities to be offered to employees in employee benefit plans

Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study

~ Advances First-in-Class Opioid with Oral Overdose-Protection ~ SAN DIEGO, CA / ACCESS Newswire / April 16, 2026 / Ensysce Biosciences, Inc...

Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs

~Continued funding underscores investor confidence and supports advancement of abuse- and overdose-resistant analgesics~ SAN DIEGO, CA / ACCESS...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results

~ Fourth Quarter Highlighted by Clinical and Regulatory Milestones Positioning PF614 for Late-Stage Advancement ~ SAN DIEGO, CA / ACCESS Newswire...

Form 8-K - Current report

Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Plans

~ Underscores Strategic Execution Plans, Regulatory Risk Mitigation Efforts, Pipeline Prioritization, and the Commercial Potential of PF614 ~ SAN...

Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology

~ Phase 1 Data Published in Journal of Opioid Management Validates First-in-Class Overdose-Limiting Opioid Technology of PF614-MPAR ~ SAN DIEGO...

Form 8-K - Current report